News

Smoking was associated with greater odds of EPI, and prevalence ranged from 21.1% to 52.1% depending on the diagnostic test used.

Real-world COMPETE SWITCH CV data at EASD 2026 linked semaglutide 2 mg escalation to 6% lower MACE risk vs switching to tirzepatide in T2D.

Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.

Ochsner Health uses multidisciplinary clinics, living donor programs, and transplant innovations to address access challenges.

Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.

Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.

Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.

Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss dosing guidelines for the recently approved efsitora alfa-gobe.

Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's approval of a new basal insulin for T2D.

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

An Ochsner transplant surgeon discusses 10,000 transplants and how new tools are expanding who can receive an organ.

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss UACR screening for patients with CKD and T1D.

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.

Topical steroid withdrawal advocate Briana Banos urged clinicians to stay curious and treat patients as experts on their own bodies.

Vogelmeier, of Philipps-University of Marburg discusses pooled data showing reduced COPD exacerbations, though most effectively in former smokers.

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.

Discover how newly cleared weekly basal insulin efsitora reshapes type 2 diabetes care—QWINT results, hypoglycemia edge, and dosing tips.

FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss trust-building, psychosocial burden, and treatment fit in psoriasis care for diverse skin tones.